Symic Bio raises $30M in series B
Matrix biology company Symic Bio Inc. (Emeryville, Calif.) raised $30 million in a series B round from new investor HEDA Ventures and existing investors Lilly Ventures, Den Danske Forskningsfond, Ally Bridge Group, InCube Ventures and Alexandria Real Estate Equities. Other undisclosed investors also participated.
CEO Ken Horne told BioCentury that the company hopes to develop partnerships in China via Ally Bridge and HEDA...
BCIQ Company Profiles